葵花葯業(002737.SZ):擬續聘立信會計師事務所
格隆匯12月6日丨葵花葯業(002737.SZ)公佈,公司於2021年12月6日召開公司第四屆董事會第十二次會議、第四屆監事會第八次會議,審議通過了《關於續聘會計師事務所的議案》。
立信會計師事務所(特殊普通合夥)為公司2020年度審計機構,其具備證券、期貨相關業務資格,具有多年上市公司審計工作經驗,有較強的專業服務能力、投資者保護能力,在擔任公司審計機構期間,勤勉盡責,客觀公允的發表了獨立審計意見,順利完成公司的審計工作。為保證公司審計工作的連續性,公司擬續聘立信會計師事務所(特殊普通合夥)為公司2021年度審計機構,聘期一年,審計費用由公司董事會提請股東大會授權管理層根據年度審計工作量及市場公允合理的定價原則確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.